VIKEN, Sweden, September 7, 2022 /PRNewswire/ — TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company’s lead drug candidate, ILB® for inhibiting infection of human cells by four dengue virus serotypes (DENV1-4), two strains of Zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) evaluated by virus particle immunofluorescence . In the study, ILB® potently inhibited infection by all strains of dengue, zika, and yellow fever virus in a concentration-dependent manner with IC50 for ILB® ranging from 31 to 343 µg/ml.
Professor Nicholas Barnes PhD PBPhS (Professor of Pharmacology and CEO, Celentyx Ltd, and one of the world’s most cited researchers https://www.webofscience.com/wos/author/record/2127569) commented :
“It is well recognized that infection with flaviviruses such as dengue, Zika virus, and yellow fever can result in catastrophic, life-threatening conditions. This underscores the clinical need for safe and effective drugs to treat these infections. What I finds particularly exciting about these results is the effects seen at the ILB® concentrations that have been reached in humans after well-tolerated doses. These findings offer hope to the millions of patients who continue to be devastated by flavivirus infections.”
TikoMed recently announced the publication of a peer-reviewed scientific article on the mode of action of ILB®. In multiple preclinical and clinical studies on a variety of neuroinflammation-induced diseases. HE B® both mobilized and modulated natural tissue repair mechanisms, released heparin-binding growth factors and restored cellular homeostasis and function.
“These results provide further evidence of TikoMed’s ILB’s unique broad-spectrum antiviral potential and mechanism of action.® drug platform. We have already initiated clinical development programs for amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI) and islet cell transplantation and plan to consider further evaluation in other diseases,” said Anders KristenssonCEO of TikoMed.
*bioRxiv is a free service for archiving and online distribution of unpublished preprints in the field of life sciences. It is operated by Cold Spring Harbor Laboratory, a non-profit research and educational institution. By posting preprints on bioRxiv, authors can make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals.
For more details on the study “A clinical-stage drug LMW-DS inhibits infection of human cells by dengue, Zika and yellow fever viruses”, please access the publication: https://www.biorxiv.org/content/10.1101/2022.08.31.503293v1.full.
Flaviviruses are responsible for the most abundant human arboviruses in terms of geographical distribution, morbidity and mortality; at least 2.5 billion people are at risk with, for example, around 100 to 400 million dengue infections per year. However, for dengue, zika or yellow fever virus infections, there is no effective anti-infective drug treatment nor for dengue or zika virus a safe and effective vaccine and prevention currently focuses on vector (mosquito) control. While the symptoms of Dengue, Zika and Yellow Fever virus infection can be mild for some, they are very serious and life threatening for others. For example, severe dengue fever is a leading cause of hospitalization and death among children and adults in Asian and Latin American countries. Similarly, Zika infection can have catastrophic consequences for pregnant women following the transmission of the virus to their fetus leading to miscarriage or birth defects, including microcephaly which can be fatal.
Contact: [email protected] or +46 42 23 84 40
International: Richard Hayhurst [email protected] or +44 7711 821527
Nordics: Ola Bjorkman [email protected] or +46 70 245 7497
This information was brought to you by Cision http://news.cision.com